PGT-P stands for preimplantation genetic testing for polygenic conditions, a newer form of embryo screening that estimates an embryo’s genetic risk for common diseases shaped by many genes at once, like heart disease, diabetes, or certain cancers. Unlike older forms of genetic testing that look for single-gene mutations (such as those causing cystic fibrosis or sickle cell disease), PGT-P uses polygenic risk scores to combine the effects of thousands of small genetic variants into an overall risk estimate. The technology has already been introduced commercially, but it sits at the intersection of promising science and serious unresolved questions about accuracy, ethics, and real-world usefulness.
How PGT-P Differs from Other Embryo Genetic Tests
If you’ve encountered genetic testing in the context of IVF, you’ve probably heard of PGT-A and PGT-M. PGT-A screens embryos for chromosomal abnormalities like extra or missing chromosomes. PGT-M tests for specific single-gene disorders where one known mutation causes a disease with high certainty. Both deal with relatively clear-cut genetic signals: either the chromosome count is right or it isn’t, or either the embryo carries the harmful mutation or it doesn’t.
PGT-P works on fundamentally different ground. Most common diseases aren’t caused by one gene. Type 2 diabetes, coronary artery disease, schizophrenia, breast cancer, and depression are all influenced by hundreds or thousands of genetic variants, each contributing a tiny nudge toward higher or lower risk. A polygenic risk score adds up all those nudges to produce a single number representing relative genetic susceptibility. PGT-P applies that scoring approach to embryos created through IVF, giving prospective parents a risk profile for each embryo across multiple conditions before deciding which to transfer.
The Technical Process Behind the Scores
Getting a polygenic risk score from an embryo is more complicated than running the same test on an adult. An embryo biopsy yields only a few cells, which means the DNA sample is tiny. Researchers and commercial labs work around this limitation by combining the embryo’s sparse genetic data with the parents’ full genome sequences. Using statistical methods, they reconstruct the likely genome the embryo inherited, then calculate risk scores from that reconstruction.
One research group described an algorithm that reconstructs embryo genomes from minimal sequencing data combined with parental genome information, producing both polygenic scores and measures of confidence in those scores. The accuracy of this reconstruction depends heavily on how well the parents’ genetic data has been organized, a process called phasing. The team developed techniques to improve parental phasing by combining different sequencing approaches, which in turn sharpens the embryo’s predicted scores.1Genetics in Medicine Open. ImputePGTA: Accurate embryo genotyping and polygenic scoring from ultra-low-pass sequencing
In a study of 110 embryos from 10 couples, researchers used a whole-genome reconstruction strategy to infer the inherited genetic sequence and then computed polygenic risk scores across 12 common conditions, including cancers, cardiometabolic diseases, and autoimmune disorders. The scores were calibrated against a large population database to convert them into predicted odds of disease.2Nature Medicine. Whole-genome risk prediction of common diseases in human preimplantation embryos From a technical standpoint, the genotyping accuracy at individual genetic positions relevant to risk scores appears to exceed 99%, and polygenic scores derived from embryos closely match those measured in newborns.3F&S Reviews. Promises and pitfalls of preimplantation genetic testing for polygenic disorders: a narrative review
How Much Difference Can Embryo Selection Actually Make?
This is where PGT-P hits a wall that the marketing materials tend to gloss over. Even if the scoring is technically accurate, the practical gains from choosing one embryo over another within the same family are modest, because siblings share most of their genetic variation.
A widely cited analysis modeled what would happen if parents selected embryos based on polygenic scores for height or cognitive ability. With a typical IVF cycle producing about five testable embryos, the predicted average gain was roughly 2.5 centimeters for height and about 2.5 IQ points for cognitive ability. Those are averages; the actual range varied from about 1 to 6 centimeters for height, with wide prediction intervals. The researchers also found that in large families, the child who scored highest on the polygenic predictor was usually not the tallest, underscoring how much environment and random variation matter.4PubMed Central. Screening human embryos for polygenic traits has limited utility Below five embryos, the predicted gain drops sharply, and many IVF cycles produce fewer than five viable embryos to choose from.
For disease risk, the situation is similar. You’re not choosing between a sick embryo and a healthy one. You’re choosing between embryos that might differ by a few percentage points in lifetime risk for a given condition. If two siblings have predicted lifetime risks of, say, 12% and 9% for type 2 diabetes, that difference is real but far from a guarantee of any particular outcome for either child.
What the Scores Do and Don’t Predict
A critical point that often gets lost: polygenic risk scores are population-level statistical tools. They tell you where someone falls on a bell curve of genetic risk compared to a reference population. They do not tell you whether a specific person will or won’t develop a disease. Two people with identical risk scores can have completely different health outcomes depending on diet, exercise, stress, environmental exposures, and plain luck.
Another limitation is that no long-term outcome data exists. The technology is too new. Validating whether embryos selected through PGT-P actually develop fewer diseases in adulthood would take decades of follow-up that simply haven’t happened yet.3F&S Reviews. Promises and pitfalls of preimplantation genetic testing for polygenic disorders: a narrative review So the entire enterprise rests on the assumption that polygenic scores validated in existing adult populations will be equally predictive for children born into different environments years from now.
The conditions PGT-P is currently marketed for tend to be common adult-onset diseases: heart disease, type 2 diabetes, certain cancers, and in some cases psychiatric conditions. Private companies have begun offering screening for genetic risk of complex diseases including psychiatric disorders, which raises its own set of concerns about how meaningful such scores are for conditions influenced heavily by life experience.5PubMed Central. Concerns about the use of polygenic embryo screening for psychiatric and cognitive traits
Pleiotropy and Unintended Genetic Trade-offs
One of the trickier scientific problems with selecting embryos based on polygenic scores is pleiotropy, the phenomenon where the same genetic variants influence multiple traits. Selecting for lower risk of one disease could, in theory, inadvertently raise the risk of another. This concern has been raised repeatedly in the scientific literature, with researchers noting that embryo selection using polygenic scores could lead to selecting for adverse traits or other unintended consequences.6PubMed Central. Problems with Using Polygenic Scores to Select Embryos
Some research, though, suggests the picture may not be as bleak as feared. One study examined a composite health index combining risk scores for 20 diseases and found that individuals with higher composite scores had decreased risk across nearly all conditions, with no significant risk increases. The correlations between genetic disease risks turned out to be mostly positive and mild, meaning that genes raising risk for one disease tended not to lower risk for others in a meaningful way.7PubMed Central. Polygenic Health Index, General Health, and Pleiotropy: Sibling Analysis and Disease Risk Reduction This is reassuring in a narrow sense, but the study looked at a specific set of common diseases, and the question of trade-offs across traits not measured remains open.
Ancestry and Who the Scores Work For
Polygenic risk scores are built from genome-wide association studies, and the vast majority of those studies have been conducted in populations of European descent. This creates a significant accuracy gap. A score trained mostly on data from white Europeans will be less predictive for someone of African, East Asian, South Asian, or Indigenous ancestry. The genetic architecture of disease risk varies across populations, and the variant weights that power these scores don’t transfer cleanly across ancestral backgrounds.
For PGT-P, this means the technology works better for some families than others based on their ancestry, which raises equity concerns on top of the access issues that already surround IVF. Families from underrepresented populations may receive scores that are less informative or potentially misleading, a problem that won’t be solved until the underlying research databases become more diverse.
Non-Medical Traits and the Intelligence Debate
The conversation around PGT-P gets especially heated when it moves beyond disease and into traits like intelligence or educational attainment. Polygenic scores exist that predict some fraction of the variation in cognitive ability, and there have been suggestions that they could be used for embryo selection within the normal range. One bioethics analysis examined how different regulatory models would apply to prediction of non-disease traits like intelligence, noting that the genetics of intelligence remains controversial both scientifically and ethically.8Journal of Medical Ethics. Three models for the regulation of polygenic scores in reproduction
The scientific controversy is partly about how little of the variation these scores capture. Intelligence is shaped by genes, but also profoundly by nutrition, education, socioeconomic environment, and countless other factors that no embryo screen can measure. The ethical controversy goes deeper: even if such selection were highly effective, many people would object to it on principle, seeing it as a step toward treating human traits as consumer options.
Ethics, Eugenics, and the Slippery Slope
The word “eugenics” comes up in virtually every serious discussion of PGT-P, and not without reason. A scoping review of the ethical literature found that in a survey of the US general population, over 90% of respondents expressed concern about polygenic embryo screening promoting eugenic thinking and practices. The review also documented widespread concern about “designer babies” and the commercialization of reproduction.9Genetics in Medicine Open. Ethical and social implications of implementing polygenic embryo screening into clinical care: A scoping review Researchers have drawn explicit parallels to early 20th-century eugenics programs that designated certain mental conditions as worthy of elimination, noting that while modern reproductive genetics differs in fundamental ways, the application of polygenic screening to psychiatric conditions revives uncomfortable echoes of that history.
Healthcare professionals have voiced their own concerns. In a qualitative study, clinicians worried about a “slippery slope” where screening expands from serious diseases to milder conditions to non-medical preferences. They also raised the issue of a “technological imperative,” the subtle pressure parents may feel to use available technology simply because it exists, potentially creating new anxieties about a child’s health before the child is even born. Because PGT-P provides risk scores before birth, the future autonomy of the child becomes a concern: the child never consented to having their genetic risk profile generated and used as a selection criterion.10PubMed. “Are we not going too far?”: Socio-ethical considerations of preimplantation genetic testing using polygenic risk scores according to healthcare professionals
Professional Society and Regulatory Positions
Given all this uncertainty, what do the medical organizations actually say? The American College of Medical Genetics and Genomics (ACMG) has issued a “points to consider” statement on the clinical utility of polygenic risk scores for embryo selection, signaling that the field considers this an area requiring caution rather than routine clinical adoption.11PubMed Central / Genetics in Medicine. Clinical utility of polygenic risk scores for embryo selection: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG) A review of normative documents on preimplantation genetic testing found that the lack of specific guidance on PGT-P is itself a problem, noting that the screening of multiple polygenic conditions simultaneously increases ethical difficulties around severity, risk assessment, autonomy, and informed decision-making.12PubMed. A review of normative documents on preimplantation genetic testing: Recommendations for PGT-P
Regulatory approaches vary globally. Some researchers have argued that professional societies and policymakers should warn parents about the limitations and risks and consider prohibiting polygenic embryo selection outright, while potentially permitting cautious use for serious late-onset diseases.13Europe PMC. Precautions for polygenic embryo selection: prohibition or cautious use In practice, countries with stricter IVF regulations (much of Europe, for instance) tend to restrict or prohibit embryo selection beyond medical necessity, while the United States has a more permissive, market-driven landscape where commercial PGT-P is already available to anyone willing to pay for it.
The Commercial Landscape
A handful of companies now offer PGT-P as an add-on to standard IVF genetic testing, typically for several hundred to a few thousand dollars on top of the already substantial cost of an IVF cycle. The marketing tends to emphasize parental empowerment and “healthier babies,” which critics argue oversells what the technology can deliver.
Researchers have argued that the commercialization of PGT-P presents risks regardless of whether it delivers accurate results. These include the promotion of selective attitudes about which children are worth having, the commodification of reproduction, and the transformation of parental responsibility in ways that put new moral burdens on prospective parents.14Nature Human Behaviour. Embryo screening and the new reproductive divide If you can screen for disease risk, the reasoning goes, do you have an obligation to do so? And if you don’t screen, are you somehow responsible for a child’s future illness? These are questions the technology creates simply by existing, even for parents who never use it.
When Lifestyle Matters More Than the Score
One of the most underappreciated facts about polygenic risk scores is that for many of the diseases PGT-P screens for, lifestyle and environment can offset genetic risk substantially. This undercuts the urgency of embryo selection for these conditions.
A study of cardiovascular disease, diabetes, and lipid levels found that healthy lifestyle reduced disease incidence by a similar proportion across all genetic risk groups. But the absolute benefit was much larger for people at high genetic risk. For type 2 diabetes, lifestyle adherence reduced absolute risk by about 12.4% in people at the very top of genetic risk, compared to about 2.8% in those at the bottom.15PubMed Central. Interactions Between Enhanced Polygenic Risk Scores and Lifestyle for Cardiovascular Disease, Diabetes, and Lipid Levels In other words, the people who stand to gain most from lifestyle changes are exactly the ones at highest genetic risk, meaning that the risk a polygenic score identifies can often be managed after birth rather than avoided through embryo selection.
Similar findings appear in other domains. Research in children and adolescents found that higher fiber intake and less screen time partly offset a genetic predisposition to obesity during childhood.16PubMed Central. Polygenic risk for obesity and its interaction with lifestyle and sociodemographic factors in European children and adolescents For depression, a study found that people with high genetic risk and an unhealthy lifestyle had more than double the risk of developing depression compared to those with low genetic risk and a healthy lifestyle, but the benefits of healthy habits held across all genetic risk categories.17Translational Psychiatry. Polygenic risk score, healthy lifestyles, and risk of incident depression The genetically driven increase in risk could be counteracted, at least partly, by how someone actually lives.
This doesn’t make PGT-P pointless, but it does put the technology in perspective. If a few percentage points of genetic risk can be matched or exceeded by eating well and staying active, the case for selecting embryos on that basis becomes harder to make, especially given the costs and ethical complications involved.
What Prospective Parents Should Know
If you’re going through IVF and a clinic offers PGT-P, a few things are worth keeping in mind. First, PGT-P does not test for certainty; it estimates relative risk. An embryo flagged as “lower risk” for a condition is not guaranteed to be free of it, and an embryo flagged as “higher risk” might never develop the disease. Second, the scores are most accurate for people of European ancestry and less reliable for other populations. Third, the practical difference between embryos from the same parents is constrained by the fact that siblings share a large fraction of their DNA. You’re choosing among relatively similar genetic profiles, not radically different ones.
Fourth, consider what you would do with the information. If you have only two or three viable embryos after an IVF cycle, the PGT-P results may not change your decision at all, especially if one embryo is clearly preferable for chromosomal or single-gene reasons. And fifth, the diseases being screened for are ones where post-birth interventions, from lifestyle changes to medications to early screening, are often highly effective. A polygenic risk score could, in principle, be just as useful run on a newborn or child as on an embryo, guiding preventive care without requiring embryo selection.
Polygenic Scores After Birth
An emerging parallel conversation focuses on using polygenic risk scores not for embryo selection but for early risk stratification in children and adults. The same scores that power PGT-P can be applied to anyone’s DNA at any point in life. A person identified as high-risk for coronary artery disease through a polygenic score could begin more aggressive cholesterol management earlier. Someone at high genetic risk for breast cancer could start screening at a younger age.
This application sidesteps the most contentious ethical issues of embryo selection while still using the genetic information constructively. It also doesn’t require the expense and physical demands of IVF. For families already undergoing IVF for fertility reasons, PGT-P adds one more layer of information. But for families considering IVF solely to access embryo screening, the calculus looks different, and many geneticists and ethicists argue the technology hasn’t yet earned that kind of commitment from patients.